Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine
- 1 May 2002
- journal article
- clinical trial
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 7 (3), 119-124
- https://doi.org/10.1016/s1078-1439(01)00182-x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Phase III Trial of Interferon Alfa-2a With or Without 13-cis-Retinoic Acid for Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2000
- Effect of Cytokine Therapy on Survival for Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2000
- SYSTEMIC THERAPY FOR RENAL CELL CARCINOMAJournal of Urology, 2000
- Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 1999
- RENAL CELL CARCINOMA: MANAGEMENT OF ADVANCED DISEASEJournal of Urology, 1999
- Health Related Quality of Life Outcomes in Patients Treated for Metastatic Kidney Cancer: A Pilot StudyJournal of Urology, 1997
- Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2Published by American Medical Association (AMA) ,1994
- Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.Journal of Clinical Oncology, 1992
- Quality of Life End Points in Cancer Clinical Trials: Review and RecommendationsJNCI Journal of the National Cancer Institute, 1989
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987